Blog

    • August 19, 2019

    Capsule Pharmacy 'Dear Doctor' Interview Series: Sara Nayeem

    *Interview of Sara Nayeem by Maya De La Rosa-Cohen; originally published as part of the Capsule 'Dear Doctor' Series, which highlights women physicians working throughout the field of healthcare. Dr. Sara Nayeem was selected three times as one of GrowthCap’s Top 40 Under 40 Growth Investors. Having earned her MD and MBA simultaneously from Yale University and worked within Merrill Lynch’s Global Healthcare Group, today she uses her knowledge and experience in both medicine and business…

  • Tiburio: Investing in Traditional Drug Development in the Era of Big Science Platforms

    For the past ten years I have been a biopharma investor at NEA, and in that time I have witnessed the drug industry truly enter the genomic age. With technologies such as gene and mRNA therapy, gene editing, CAR-T and other cell therapies, we are living in a time of unprecedented potential (and peril, as demonstrated by Chinese researcher He Jiankui’s rogue experimentation with gene editing on two human embryos). The public markets (and in some cases, strategic acquirors) have valued these…

  • True Partnership: Our Approach to Healthcare Innovation and Company Building

    NEA will invest more than $1.25B in healthcare companies in the next three years. Here's what you should know. As a global, diversified VC firm with more than $20B in committed capital, we believe that size confers some distinct advantages. But after almost a decade as part of NEA’s healthcare practice, I’ve learned that our scale isn’t always well understood. The breadth of our activity can obfuscate the depth of our expertise. From the perspective of an entrepreneur or investor who is…

  • Recent FDA Decisions Signal Shift, with Troubling Implications for Patients and Medical Innovation

    Drug development has always required a surfeit of intestinal fortitude. It can take hundreds of millions of dollars and a decade or more to bring a new drug to market, and each phase of development—from structuring a clinical trial to securing reimbursement from insurers—carries substantial risk. No entity plays a more central role in the process than U.S. Food and Drug Administration (FDA), which is charged with evaluating the safety and efficacy of new drugs, as well as determining the…

  • More than a Health Plan...

    If innovation comes in waves, then the managed care industry may very well be in the midst of a tsunami. The last seismic shift in the industry was arguably back in the nineties, resulting from legislation like the Balanced Budget Act—which imposed new payment structures, stricter compliance, and increased incentives for efficiency. Health Plan operation and administration was forced to adapt, and even though this period coincided with the explosion of the internet—emerging technologies were…